Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Contact Email
Phone number
Website URL
Similar Companies1000
Nanna Therapeutics
Nanna Therapeutics is a drug discovery company.
Sector
Subsector
Keywords
Location
total rounds
total raised
Advanced Proteome Therapeutics
Advanced Proteome Therapeutics is a biotech company that develops novel therapeutics for cancer treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
Tamir Biotechnology
Tamir Biotechnology develops therapeutic drugs for cancer and other pathological conditions.
Sector
Subsector
Keywords
Location
total rounds
total raised
Aligos Therapeutics
Aligos Therapeutics develops antiviral therapies for hepatitis B, coronaviruses, and nonalcoholic steatohepatitis.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Johnson & Johnson
announced date
Financials
Funding Rounds9
Number of Funding Rounds
Money Raised
Their latest funding was raised on 24.12.2014. Their latest investor BioAdvance. Their latest round Debt Financing
Canaan Partners
Canaan Partners is an early stage venture capital firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that funds life sciences startups.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
5AM Ventures
5AM Ventures is a venture capital firm that invests in early-stage companies in the life sciences industry.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors7
Number of lead investors
Number of investors
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that funds life sciences startups.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Robin Hood Ventures
Robin Hood Ventures is a group of angel investors in Philadelphia.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Canaan Partners
Canaan Partners is an early stage venture capital firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
Timothy Shannon
For more than 25 years, Tim Shannon has been an entrepreneur, executive, researcher, professor, and practicing physician in pulmonary and critical care medicine. A Canaan investor since 2009, we rely on Tim's operating experience to help companies grow from their earliest stages to funded companies creating value through partnerships, M&A and IPOs. Tim was one of the early institutional investors and remains on the board of CytomX Therapeutics, which completed a $92 million initial public offering in October 2015 (NASDAQ: CTMX). He was a co-lead Series A investor in Civitas Therapeutics, which was acquired by Acorda Therapeutics in October 2014 for $525 million, and a lead Series A investor in Novira Therapeutics, Inc. which was acquired by Johnson & Johnson in December 2015. In addition, he serves on the boards of IDEAYA Biosciences, NextCure, Spyryx Biosciences and Vivace Therapeutics.. Prior to Canaan, Tim was president and chief executive officer of CuraGen, a publically traded biopharmaceutical company focused on oncology, after serving as executive vice president of R&D and chief medical officer. Earlier he was the senior vice president and head of global clinical development for Bayer's Pharmaceutical Business Group. Tim began his career as assistant professor of the pulmonary and critical care division at Yale University School of Medicine. Tim received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, earned his medical degree from the University of Connecticut, and has a B.A. in chemistry from Amherst College.
current job
People
Founders3
Osvaldo Flores
Osvaldo (Lalo) Flores, Ph.D., is the co-founder, president and chief scientific officer of Novira Therapeutics. He has more than 18 years of experience in pharmaceutical research and development across multiple therapeutic areas and has held senior positions at biotechnology and large pharmaceutical companies. Prior to co-founding Novira, he held multiple leadership roles at Merck, including director of antiviral research as well as senior director and department head of molecular endocrinology. During his tenure at Merck, he was responsible for developing and delivering the strategy for research and development, managing the pipeline from target identification through clinical proof of concept across multiple therapeutic areas and contributed to the identification and advancement of over 10 drug candidates to preclinical and clinical development. Dr. Flores began his career in industry at Tularik, a company acquired by Amgen in 2004, as one of the initial employees. At Tularik he led discovery efforts for human immunodeficiency virus (HIV), cytomegalovirus (CMV) and hepatitis C (HCV) programs that produced a clinical candidate for CMV and the discovery of CDK9/Cyclin T1 as a drug target. Dr. Flores holds a doctorate in biochemistry and molecular biology from Rutgers University and University of Medicine and Dentistry of New Jersey (UMDNJ).
current job
organization founded
Osvaldo Flores
George Hartman
George D. Hartman, Ph.D., is the co-founder and vice president of chemistry and pre-clinical development of Novira Therapeutics. Prior to this role, Dr. Hartman was at Merck for over 35 years, rising to the level of executive director of medicinal chemistry, where he was responsible for the discovery and development of clinical candidates across multiple therapeutic areas, including cancer, schizophrenia, insomnia, Parkinson’s, inflammation, ophthalmics and anti-infectives. Dr. Hartman was the lead inventor for Aggrastat®, an anti-platelet agent used worldwide in the treatment of ischemic coronary disease. In addition, he and his group identified and brought to the clinic 12 drug candidates that have been evaluated in Phase 2 or Phase 3 trials. When he retired from Merck in 2008, Dr. Hartman had responsibility for over 120 researchers across key project areas. He is an author or co-author on more than 170 peer-reviewed papers and more than 130 issued U.S. patents, lectured at U.S. and foreign universities, and has given more than 40 invited talks. Dr. Hartman is the past chair of the Gordon Conference on Medicinal Chemistry, has organized more than 20 symposia and conferences and held the position of editor of ChemMedChem. Dr. Hartman holds a doctorate in organic chemistry from The Ohio State University.
current job
organization founded
George Hartman
Ali Munawar
Ali Munawar is the Founding CEO at Orthogon Therapeutics, LLC. He attended KU Leuven.
current job
organization founded
Ali Munawar
Employee Profiles13
Osvaldo Flores
Co-Founder and President & Chief Scientific Officer
Nathaniel Brown
Chief Clinical Advisor & Acting Chief Medical Officer
Klaus Klumpp
Vice President of Discovery in Charge of Biology